Table 2. Serological characteristics of subjects included in the regional SLE cohort.
| All patients (n=351) | SLE without psoriasis (n=339) | SLE with psoriasis (n=12) | P value | |
|---|---|---|---|---|
| Variables * , n (%) | ||||
| Anti-dsDNA (+) | 176 (50.1) | 173 (51.0) | 3 (25.0) | 0.09 |
| Anti-Sm (+) | 30 (8.5) | 29 (8.6) | 1 (8.3) | 1.0 |
| Anti-U1-RNP (+) | 136 (38.7) | 128 (37.8) | 8 (66.7) | 0.07 |
| Anti-SSA (+) | 168 (47.9) | 161 (47.5) | 7 (58.3) | 0.6 |
| Anti-SSA/Ro52 (+) | 130 (37.0) | 124 (36.6) | 6 (50.0) | 0.4 |
| Anti-SSA/Ro60 (+) | 127 (36.2); n=349 | 120 (35.6); n=337 | 7 (58.3) | 0.1 |
| Anti-SSB (+) | 85 (24.2) | 82 (24.2) | 3 (25.0) | 1.0 |
| aCL | ||||
| IgG (+) | 79 (22.5) | 78 (23.0) | 1 (8.3) | 0.3 |
| IgA (+) | 24 (6.8); n=232 | 23 (10.3); n=224 | 1 (12.5); n=8 | 0.4 |
| IgM (+) | 23 (6.6); n=349 | 22 (6.5); n=337 | 1 (8.3) | 0.6 |
| aβ2GPI | ||||
| IgG (+) | 59 (16.8); n=349 | 58 (17.2); n=337 | 1 (8.3) | 0.7 |
| IgA (+) | 36 (10.3); n=232 | 34 (15.2); n=224 | 2 (25.0); n=8 | 0.4 |
| IgM (+) | 43 (12.3); n=349 | 42 (12.5); n=337 | 1 (8.3) | 1.0 |
| Lupus anticoagulant test (+) | 99 (28.2); n=318 | 95 (30.9); n=307 | 4 (36.4); n=11 | 0.7 |
| Antiphospholipid syndrome† | 57 (16.2) | 55 (16.2) | 2 (16.7) | 1.0 |
| Anti-CCP (+) | 18 (5.1); n=254 | 18 (7.3); n=246 | 0 (0.0); n=8 | N/A |
| Rheumatoid factor (+) | 36 (10.3); n=153 | 35 (23.6); n=148 | 1 (20.0); n=5 | 1.0 |
| Low C3 | 64 (18.2) | 64 (18.9) | 0 (0.0) | N/A |
| Low C4 | 157 (44.7) | 151 (44.5) | 6 (50.0) | 0.8 |
*
Data from last available visit (ever positivity).
†
According to the Sydney criteria.53 In case of missing values, the total number of observations is indicated.
aCL, anticardiolipin antibodies; aβ2GPI, anti-β2-glycoprotein-I; CCP, cyclic citrullinated peptide; dsDNA, double-stranded DNA; IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M; N/A, not applicable; Sm, Smith antigen; SSA, Sjögren’s syndrome A; SSB, Sjögren’s syndrome B; U1-RNP, U1-ribonucleoprotein.